Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (Q34013882)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint |
scientific article |
Statements
1 reference
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (English)
1 reference
Alan W Partin
1 reference
Connie Collins
1 reference
Michael A Carducci
1 reference
Mario A Eisenberger
1 reference
John T Isaacs
1 reference
Roberto Pili
1 reference
Victoria J Sinibaldi
1 reference
Janet S Walczak
1 reference
Samuel R Denmeade
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference